This is unpublished

Damian J.
Green
M.D.

he, him, his
Physician & Research Faculty
Pinned
Academic
Associate Professor, Clinical Research Division, Fred Hutchinson Cancer Research Center
Associate Professor, Division of Medical Oncology, University of Washington
Sites of Practice
Seattle Cancer Care Alliance

Photo: SCCA

Education, Training, Board Certifications

  • M.D., The Ohio State University 
  • Residency, The Ohio State University  
  • Fellowship, UW/Fred Hutch 
  • Medical Oncology, American Board of Internal Medicine
  • Internal Medicine, American Board of Internal Medicine

Clinical Expertise 

  • Hematopoietic stem cell transplantation 
  • Immunotherapy 
  • Multiple myeloma 
  • Waldenström’s Macroglobulinemia 
  • Amyloidosis

Affiliations 

 

Publications

 

Research and/or clinical interests 

Dr. Damian Green develops new immunotherapies that harness the power of the immune system to treat and ultimately eradicate multiple myeloma and lymphoma. A major research focus is radioimmunotherapy, in which radioactive particles are linked to cancer-targeting molecules called antibodies to deliver deadly radiation straight to cancer cells while sparing healthy tissues. Dr. Green also studies a type of immunotherapy called bispecific antibody therapy in which a two-pronged antibody brings together cancer-killing immune cells and cancer cells. Another major focus of his work is the development and clinical evaluation of a form of genetically engineered T-cell therapy (called CAR T-cell therapy) for patients with myeloma. 

 

Dr. Green’s research is supported by three competitive federal grants on which he is lead investigator and through a variety of non-profit research foundation initiatives focused on improving stem cell transplant outcomes, delivering targeted radiation to tumor cells and improving the efficacy of chimeric antigen receptor (CAR) T-cell therapy. He is the principal investigator on numerous clinical trials, including studies to evaluate CAR T-cell therapy in multiple myeloma. Dr. Green is also a lead investigator on a multi-center network grant through the Multiple Myeloma Research Foundation (MMRF) designed to define optimal tumor and host signatures for immunotherapy of multiple myeloma. He is also co-leader on an initiative with the Allen Institute for Immunology focused on characterizing the dysregulation of immune function in multiple myeloma. In addition, he is co-investigator on over 20 clinical trials for patients with multiple myeloma or lymphoma.